Tag: ASX:CSL

CSL

CSL

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

Sorry, but this content is restricted to our members.

Please login with your account or register for a free trial. If your trial has expired, then you may renew it here.

If you are having an issue with your account, then please get in touch with us.

CSL has lobbed a US$11.7bn all cash public tender offer for Switzerland based specialty drug company Vifor Pharma.

The acquisition is being funded via a combination of a private placement, SPP and cash/debt, with commencement around 18 Jan-22.

CSL is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.

Buy between the $240 – $270 price range.